The Oral Histone Deacetylase Inhibitor LBH589 Is a Potential and Promising Therapeutic Agent in Multiple Myeloma after at Least Two Lines of Chemotherapy Including Bortezomib or Lenalidomide

Publisher： Karger

E-ISSN： 2296-5262|33|4|183-186

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.33, Iss.4, 2010-03, pp. : 183-186

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment of Multiple Myeloma: Thalidomide-, Bortezomib-, and Lenalidomide-Induced Peripheral Neuropathy

By  

Oncology Research and Treatment, Vol. 37, Iss. 9, 2014-08 ,pp. : 506-513

Karger

Access to resources Recommend Favorite

Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 7-1048, Iss. 1, 2015-10 ,pp. : 74-83

John Wiley & Sons Inc

Access to resources Recommend Favorite

Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 171, Iss. 1, 2015-10 ,pp. : 74-83

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results from Two Consecutive Studies of Consolidation Therapy after Autologous Transplant for Multiple Myeloma: Thalidomide, Dexamethasone, and Clarithromycin or Lenalidomide, Dexamethasone, and Clarithromycin

By  

Acta Haematologica, Vol. 137, Iss. 3, 2017-03 ,pp. : 123-131

Karger

Access to resources Recommend Favorite

Severe Epidermal Necrolysis after Bortezomib Treatment for Multiple Myeloma

By  

Acta Haematologica, Vol. 118, Iss. 2, 2007-05 ,pp. : 65-67

Karger

Access to resources Recommend Favorite